FIBROGEN ($FGEN) posted quarterly earnings results on Monday, March 17th. The company reported earnings of -$0.08 per share, beating estimates of -$0.14 by $0.06. The company also reported revenue of $3,140,000, missing estimates of $25,408,200 by $-22,268,200.
You can see Quiver Quantitative's $FGEN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
FIBROGEN Hedge Fund Activity
We have seen 22 institutional investors add shares of FIBROGEN stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRIMECAP MANAGEMENT CO/CA/ removed 5,295,101 shares (-53.4%) from their portfolio in Q4 2024, for an estimated $2,803,755
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 2,108,544 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,116,474
- JPMORGAN CHASE & CO removed 1,672,988 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $885,847
- AQR CAPITAL MANAGEMENT LLC removed 1,320,866 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $527,553
- GSA CAPITAL PARTNERS LLP removed 1,095,866 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $580,261
- PENNANT INVESTORS, LP removed 768,400 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $306,898
- RENAISSANCE TECHNOLOGIES LLC added 605,572 shares (+80.4%) to their portfolio in Q4 2024, for an estimated $320,650
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
